Medicine
Egrifta WR kit
Egrifta WR kit is a prescription medicine containing Tesamorelin for subcutaneous use, marketed by Theratechnologies, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store EGRIFTA WR 11.6 mg vial at room temperature at 20°C to…
Key facts
- Active ingredient (INN)
- Tesamorelin
- Brand
- Egrifta WR
- Dosage form
- Kit
- Route
- Subcutaneous
- Packs
- 1 kit
- Marketing authorisation holder
- Theratechnologies
- Manufacturer
- Theratechnologies
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store EGRIFTA WR 11.6 mg vial at room temperature at 20°C to 25°C (68°F to 77°F) in the original box to protect from light, excursions permitted to 15°C to 30°C (59°F to 86°F). Store the Injection box (containing Bacteriostatic Water for Injection, syringes, needles and alcohol swabs) at room temperature at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01AC06 Tesamorelin
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 July 2025
- Identifiers
- RxCUI 2719314, 2719316DailyMed set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75NDC 62064-381Application BLA022505
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 box * 1.3 mL in 1 vial * 30 mL in 1 bottle | 62064-381-04 | Theratechnologies | 15 July 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 November 2010 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tesamorelin kit.
Clinical summary
Tesamorelin is a prescription medicine indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, among other approved uses. It is available as kits for subcutaneous use. MedsAcross supplies Tesamorelin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TesamorelinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EGRIFTA SV prescribing information (Theratechnologies) · U.S. National Library of Medicine, DailyMed
Need Egrifta WR kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.